



**Atrial Fibrillation Management Options
Evidence Review Group, July 16th, 2010
Simches Research Building, Massachusetts General Hospital
Conference Room 3130**

Meeting Agenda

Time	Item	Comment
10:00 am	Welcome and introductions Declaration of interests	Steve Pearson, ICER President All members, staff and observers to introduce themselves and declare any relevant interests
10:15 am	Setting the scene <ul style="list-style-type: none">▪ Introduction to ICER▪ Methodology▪ Process for the day	Steve Pearson
10:30 am	Clinical effectiveness review <ul style="list-style-type: none">▪ Background on ICER systematic review▪ Findings of the review	Dan Ollendorf, ICER Chief Review Officer
11:30 am	Continued reflection and deliberation on the clinical effectiveness review	Steve Pearson
12:00 pm	Break and get lunch	

Time	Item	Comment
12:15 pm	<i>Working lunch</i> Economic Model <ul style="list-style-type: none"> ▪ Structure of the model ▪ Inputs ▪ Findings 	Marc Silverstein, ICER Chief Decision Scientist
1:15 pm	Continued reflection and deliberation on the economic model results	Steve Pearson
2:00 pm	Break	Coffee/ tea, refreshments
2:15 pm	Deliberation on Integrated Evidence Ratings for AF Comparison Sets: <ul style="list-style-type: none"> ▪ 1°/2° LACA, Rate/Rhythm Control ▪ MISA vs. 2° LACA ▪ Dronedarone, Amiodarone, Rate Control ▪ Dabigatran vs. Guideline Care ▪ WATCHMAN vs. Guideline Care 	Steve Pearson
3:15 pm	Conclusions <ul style="list-style-type: none"> ▪ Final thoughts on the meeting ▪ Next steps 	Steve Pearson
3:30 pm	Close of meeting	